Navigation Links
Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
Date:6/5/2008

EXTON, Pa., June 5 /PRNewswire/ -- BioTrends Research Group, Inc. released its third annual TreatmentTrends (TM): Psoriasis publication, providing insight into the management of psoriasis. This report is based on responses to an online survey completed by 102 US Dermatologists in April 2008.

According to the study, the majority of Dermatologists reported an increase in their use of biologics for the treatment of psoriasis in the past year, particularly in patients with moderate psoriasis. While the increased use of biologics was seen across the board, certain physician types, particularly those newer to practice, seem to be more aggressive in their use of these agents. Amgen/Wyeth's Enbrel continues to hold its position as market leader amongst the biologics, however, Abbott's Humira has increased its share significantly in the past year, and Dermatologists expect its growth to continue, primarily at the expense of Enbrel. Genentech/Xoma's Raptiva and Astellas' Amevive are rarely used with a collective share of less than 10%.

Despite the increased use of biologics, topical agents remain the most commonly prescribed therapy for psoriasis. Warner Chilcott's Taclonex, continues to hold its position as market leader among topical agents, although Galderma's Clobex is perceived to have significant advantages on certain attributes, most notably around its formulation. While the use of oral agents to treat psoriasis increases with disease severity, less than one-third of patients with severe psoriasis are on oral therapies. Methotrexate and Stiefel's Soriatane are the most commonly prescribed oral agents to treat psoriasis, and each is perceived to have unique advantages and disadvantages. Similar to oral agents, the use of phototherapy to treat psoriasis increases with disease severity, although only about one-fifth of patients with severe psoriasis are receiving phototherapy treatment.

For all treatment types (topicals, orals, biologics), long-term safety is the most important attribute. While all products fall short on this attribute compared to its importance, Dermatologists do perceive there to be significant safety differences between products in each product class, and perceived safety seems to be an important factor in brand preference. Moreover, in a ranking exercise of twelve attributes, "safe when used long term" was the attribute of greatest needs for new products in development to treat psoriasis. Time will tell whether the new IL-12 agents, such as Centocor's ustekinumab and Abbott's ABT-874 will be able to penetrate the TNF alpha inhibitor dominance in the Dermatology setting although interest in these agents is high.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (http://www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):